| Ytd | -6.54% | |
| 1y | -25.52% |
| Open | 1.40 | Prev Close | 1.44 | Low | 1.40 | High | 1.46 | Mkt Cap | 86.95M |
| Vol | 255.73K | Avg Vol | 745.35K | EPS | -0.68 | P/E | N/A | Forward P/E | -1.25 |
| Beta | 0.34 | Short Ratio | 10.99 | Inst. Own | 7.51% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 1.33 | 200-d Avg | 1.49 | 1yr Est | 12.63 |
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph
Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (G
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph
Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Ap
Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an
THIO-104 evaluates the efficacy of MAIA's telomere targeting agent, ateganosine, administered in